FDA Advisory Committees Reject Oxycodegol (NKTR-181) Application

FDA advisory committees rejected the new drug application for oxycodegol, an opioid analgesic, due to a lack of data regarding it’s potential for abuse...

Source: The Rheumatologist - February 19, 2020 Category: Rheumatology Authors: Michele B. Kaufman, PharmD, BCGP Tags: Analgesics Drug Updates FDA NKTR-181 opioid oxycodegol Pain Management U.S. Food and Drug Administration (FDA) Source Type: research